These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24111823)

  • 21. Guideline for the management of chronic obstructive pulmonary disease--2011 update.
    Abdool-Gaffar MS; Ambaram A; Ainslie GM; Bolliger CT; Feldman C; Geffen L; Irusen EM; Joubert J; Lalloo UG; Mabaso TT; Nyamande K; O'Brien J; Otto W; Raine R; Richards G; Smith C; Stickells D; Venter A; Visser S; Wong M;
    S Afr Med J; 2011 Jan; 101(1 Pt 2):63-73. PubMed ID: 21526617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How should we define and classify exacerbations in chronic obstructive pulmonary disease?
    Trigueros Carrero JA
    Expert Rev Respir Med; 2013 Apr; 7(2 Suppl):33-41. PubMed ID: 23551022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease.
    Ohlmeier S; Vuolanto M; Toljamo T; Vuopala K; Salmenkivi K; Myllärniemi M; Kinnula VL
    J Proteome Res; 2008 Dec; 7(12):5125-32. PubMed ID: 19367700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary rehabilitation and clinical trial design in patients with severe COPD.
    Springmeyer SC; Casaburi R; Make B; Jones P; Wise R
    COPD; 2008 Oct; 5(5):305-9. PubMed ID: 18972279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes and markers in the assessment of chronic obstructive pulmonary disease.
    Jones PW; Agusti AG
    Eur Respir J; 2006 Apr; 27(4):822-32. PubMed ID: 16585091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials.
    Woodruff PG
    Proc Am Thorac Soc; 2011 Aug; 8(4):350-5. PubMed ID: 21816991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biomarkers in COPD--do we need them?].
    Batura-Gabryel H
    Pneumonol Alergol Pol; 2011; 79(2):144-50. PubMed ID: 21351067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical utility of biomarkers in asthma and COPD.
    Snell N; Newbold P
    Curr Opin Pharmacol; 2008 Jun; 8(3):222-35. PubMed ID: 18468485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and biochemical markers of obstructive lung disease in the general population.
    Dahl M
    Clin Respir J; 2009 Apr; 3(2):121-2. PubMed ID: 20298391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations for epidemiological studies on COPD.
    Bakke PS; Rönmark E; Eagan T; Pistelli F; Annesi-Maesano I; Maly M; Meren M; Vermeire Dagger P; Vestbo J; Viegi G; Zielinski J; Lundbäck B;
    Eur Respir J; 2011 Dec; 38(6):1261-77. PubMed ID: 22130763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary biomarkers in chronic obstructive pulmonary disease.
    Barnes PJ; Chowdhury B; Kharitonov SA; Magnussen H; Page CP; Postma D; Saetta M
    Am J Respir Crit Care Med; 2006 Jul; 174(1):6-14. PubMed ID: 16556692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability.
    Sapey E; Bayley D; Ahmad A; Newbold P; Snell N; Stockley RA
    Thorax; 2008 Jun; 63(6):493-9. PubMed ID: 18057097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptomics, proteomics and metabolomics driven biomarker discovery in COPD: an update.
    Ghosh N; Dutta M; Singh B; Banerjee R; Bhattacharyya P; Chaudhury K
    Expert Rev Mol Diagn; 2016 Aug; 16(8):897-913. PubMed ID: 27267972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological markers in induced sputum of patients with different phenotypes of chronic airway obstruction.
    Bartoli ML; Di Franco A; Vagaggini B; Bacci E; Cianchetti S; Dente FL; Tonelli M; Paggiaro PL
    Respiration; 2009; 77(3):265-72. PubMed ID: 19075557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers in the management of COPD.
    Lacoma A; Prat C; Andreo F; Domínguez J
    Eur Respir Rev; 2009 Jun; 18(112):96-104. PubMed ID: 20956129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers, subgroup evaluation, and clinical trial design.
    Baker SG; Kramer BS; Sargent DJ; Bonetti M
    Discov Med; 2012 Mar; 13(70):187-92. PubMed ID: 22463794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Trial end-point in chronic obstructive pulmonary disease (COPD): minimal clinically important difference].
    Gillissen A; Buhl R; Kardos P; Puhan M; Rabe KF; Rothe T; Sauer R; Welte T; Worth H; Menz G
    Pneumologie; 2008 Mar; 62(3):149-55. PubMed ID: 18320495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD.
    Bihlet AR; Karsdal MA; Bay-Jensen AC; Read S; Kristensen JH; Sand JMB; Leeming DJ; Andersen JR; Lange P; Vestbo J
    Chest; 2015 Jul; 148(1):16-23. PubMed ID: 25856563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.
    Hollander Z; DeMarco ML; Sadatsafavi M; McManus BM; Ng RT; Sin DD
    Chest; 2017 Feb; 151(2):455-467. PubMed ID: 27693595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systems Medicine: from molecular features and models to the clinic in COPD.
    Gomez-Cabrero D; Menche J; Cano I; Abugessaisa I; Huertas-Migueláñez M; Tenyi A; Marin de Mas I; Kiani NA; Marabita F; Falciani F; Burrowes K; Maier D; Wagner P; Selivanov V; Cascante M; Roca J; Barabási AL; Tegnér J
    J Transl Med; 2014 Nov; 12 Suppl 2(Suppl 2):S4. PubMed ID: 25471042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.